SCHEMBL4910563

SCHEMBL4910563

CS(=O)(=O)Nc1cccc(Nc2nc(NCc3cccc(C(F)(F)F)c3)c3nc[nH]c3n2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 10/20 0.45
IP6K1 Q92551 1/20 0.45
IP6K3 Q96PC2 1/20 0.45
IP6K2 Q9UHH9 1/20 0.45
JAK3 P52333 1/20 0.44
STAT6 P42226 1/20 0.41
NPY5R Q15761 1/20 0.41
CDK1 P06493 1/20 0.41
SLC2A1 P11166 1/20 0.40
ULK1 O75385 1/20 0.40
PTK2B Q14289 1/20 0.40
PDE5A O76074 2/20 0.40
CDK2 P24941 1/20 0.40
MAPK1 P28482 1/20 0.40
MAPK8 P45983 1/20 0.40
CSNK1A1 P48729 1/20 0.40
CSNK1D P48730 1/20 0.40
CDK7 P50613 1/20 0.40
CCNH P51946 1/20 0.40
MNAT1 P51948 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916374 0.88 PDE5A (0.50) PTK2PDE5AMAPK1
SCHEMBL4917274 0.87 PTK2 (0.42) PTK2PDE5AMAPK1
SCHEMBL4909992 0.87 PDE5A (0.43) PTK2JAK3PDE5AMAPK1
SCHEMBL4912787 0.87 PTK2 (0.51) PTK2CDK1ULK1PTK2BPDE5A
SCHEMBL4919702 0.87 PDE5A (0.42) PTK2STAT6CDK1PDE5AMAPK1
SCHEMBL4914819 0.86 PDE5A (0.44) PTK2JAK3PDE5A
SCHEMBL4917319 0.85 PTK2 (0.45) PTK2PTK2BPDE5A
SCHEMBL4917738 0.85 MAPT (0.46) PTK2JAK3STAT6CDK1PDE5A
SCHEMBL4920844 0.85 CYP1A2 (0.55) PTK2JAK3PDE5AMAPK1
SCHEMBL4918965 0.84 PTK2 (0.50) PTK2CDK1PDE5ACDK2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors NOVARTIS AG (CH) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors GRK4, JAK2, ALK PTK2 1036/4885IP6K1 3638/4885IP6K3 2773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.